3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
3
Fluorodeoxyglucose F18
3
FAPI-46
2
romidepsin
1
repotrectinib
1
regorafenib
1
pralsetinib
1
pembrolizumab
1
fludarabine phosphate
1
alectinib
1
Specimen Handling
1
Quality of Life
1
Patient Reported Outcome Measures
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Lactones
1
Interleukin-13
1
Immunotherapy
1
Drug Therapy
1
Depsipeptides
1
Cyclophosphamide
1
Cryosurgery
1
Clinical Trials, Phase II as Topic
1
Biopsy
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
regorafenib
×
NET
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled